Syndax Pharma

Q2 FY2026 EarningsQ2 FY26 results slightly missed consensus on the top line but demonstrated better-than-expected bottom-line performance. Revenue of $72.8M was 8.25% below the $79.3M estimate, primarily due to lower collaboration revenue despite Revuforj sales growing 91% YoY. GAAP EPS of -$0.55 beat the consensus mean of -$0.46 (and was within the $0.33 to $0.67 range), driven by disciplined SG&A spending. Management maintained FY26 OPEX guidance, while multiple Phase 2 clinical catalysts in Q4 FY26 remain the primary drivers for near-term valuation.